ArticleDiscover oncology2025
Myelodysplastic syndromes with del(20q) transformed into B-lineage acute lymphoblastic leukemia remaining with del(20q): a case report with literature review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe transformation of myelodysplastic syndromes (MDS) into acute myeloid leukemia (AML) is common, while it is extremely rarely for acute lymphoblastic leukemia (ALL) transformation. Herein, we described the clinical and cytogenetic features of a case of MDS with del(20q) transformed into B-lineage ALL (B-ALL) remaining with del(20q). CASE PRESENTATION: A 66-year-old Chinese man who presented with pancytopenia, bone marrow hypercellularity and obvious megakaryocytes dysplasia were admitted for treatment. Karyotype analysis of leukemic cells revealed the clonal abnormality of del(20q) and he was diagnosed with MDS carrying del(20q). He was administrated with Danazol, cyclosporin A, and lenalidomide for 3 months, and then discontinued due to poor efficacy, severe swelling and aching of gum. He was subsequently treated with Chinese herbs and uninterrupted platelet infusion. After 41 months, this patient evolved into B-ALL. Cytogenetics demonstrated that in addition to the previous abnormality of del(20q), an emerging clonal abnormality of + 21 was observed. Unfortunately, the patient failed to achieve remission after receiving conventional treatment and other symptomatic supportive treatment.
conclusionThis study reported a rare case of B-ALL with del(20q) following MDS with del(20q), and conducted a literature review to explore the clinical features and potential mechanisms of disease transformation in patients with MDS progression to ALL. Collectively, this study will help enrich the knowledge of MDS progression to ALL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.